New Stock News | Bonasia's Hong Kong IPO Prospectus Invalidated
Bonasia (Hangzhou) Pharmaceutical Technology Co., Ltd. (short name: Bonasia) submitted its Hong Kong stock offering prospectus on February 11, 2026, which will expire 6 months later on August 11, 2026.
Bonasia (Hangzhou) Pharmaceutical Technology Co., Ltd. (abbreviated as Bonasia) submitted its Hong Kong IPO prospectus on February 11, 2026, which will expire six months later on August 11, 2026. At the time of submission, CISI FIN and ICBC International were its joint sponsors.
According to the previously disclosed prospectus, Bonasia is a clinical contract research organization (CRO) headquartered in Hangzhou, China, dedicated to empowering innovative drug clinical research through digitization. The company's core business is to provide clinical trial technical services for pharmaceutical and biotechnology companies both domestically and internationally, aiming to accelerate the R&D and commercialization processes of chemical drugs and biological products.
Related Articles
Palo Alto Networks (PANW.US) is actively seeking acquisition opportunities and has attempted to acquire Datadog (DDOG.US) and Okta (OKTA.US).
US Stock Market Move | Kanzhun Ltd. Sponsored ADR (BZ.US) surged over 18% with Q2 revenue increasing by 14.1% year-on-year.
US Stock Market Move | The MSCI index exclusion risk strikes again, and Strategy (MSTR.US) has dropped over 4%.
Palo Alto Networks (PANW.US) is actively seeking acquisition opportunities and has attempted to acquire Datadog (DDOG.US) and Okta (OKTA.US).
US Stock Market Move | Kanzhun Ltd. Sponsored ADR (BZ.US) surged over 18% with Q2 revenue increasing by 14.1% year-on-year.
US Stock Market Move | The MSCI index exclusion risk strikes again, and Strategy (MSTR.US) has dropped over 4%.
RECOMMEND
